Aims: Somatic mutations in genes encoding chromatin remodellers have been reported recently in several cancer types, including approximately half of cholangiocarcinomas. One of the most commonly mutated chromatin remodellers in cholangiocarcinoma is the Polybromo-1 (PBRM1) gene located on chromosome 3p21, which encodes a subunit of the SWI/SNF complex. The aim of this study was to determine the timing of PBRM1 mutations in biliary carcinogenesis. Methods and results: In order to accomplish this goal, we used immunohistochemistry to assess PBRM1 protein expression in a series of precursor lesions and invasive biliary carcinomas. Previous studies have correlated loss of protein expression on immunohistochemistry with inactivating mutations in this tumour suppressor gene. We found that PBRM1 loss occurred in approximately 26% of invasive cancers, but PBRM1 expression was retained in all biliary intra-epithelial neoplasia (BilIN) specimens, including 25 intrahepatic BilINs and 19 gallbladder BilINs. Conclusions: These findings indicate that PBRM1 mutation (and resultant loss of expression) is a late event during biliary carcinogenesis. In addition, we confirm a lack of prognostic significance of PBRM1 status in invasive intrahepatic cholangiocarcinoma. This study provides important insights into the basic mechanisms of chromatin remodelling genes in carcinogenesis.
PBRM1 loss is a late event during the development of cholangiocarcinoma
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Introduction
The genes involved in the establishment of chromatin structure, such as those coding for members of the SWItch/Sucrose Non-Fermentable (SWI/SNF) complex, are mutated frequently in a number of human cancers. [1] [2] [3] [4] [5] [6] [7] A critical member of the SWI/ SNF complex is encoded by the PBRM1 gene (Polybromo-1, pb1) on chromosome 3p21. The PBRM1 protein (also known as BAF180) is a subunit of the SWI/SNF complex and plays an ATP-dependent chromatin remodelling role, contributing to transcriptional regulation by altering chromatin structure and controlling the accessibility of DNA. 8, 9 Somatic mutations in PBRM1 have been reported in multiple tumour types. Jiao et al. first reported that PBRM1 is mutated frequently in biliary carcinoma, describing somatic mutations of this gene in 17% of intrahepatic cholangiocarcinomas (ICCs) and in 25% of gallbladder carcinomas. 2 An independent study identified PBRM1 mutations in approximately 10% of cholangiocarcinomas, with enrichment in ICC, 9 while a more recent study investigating mutational status of PBRM1 with immunohistochemistry reported that 23% of ICCs lack PBRM1 expression. 10 Interestingly, in addition to PBRM1, mutations in other genes influencing chromatin organization, including ARID1A, BAP1 and SMARCB1 have been identified in cholangiocarcinoma. 2, 9 Notably, Jiao et al. documented mutations in at least one chromatin-remodelling gene in 47% of cholangiocarcinomas, 2 highlighting aberrant chromatin remodelling as a crucial step in biliary carcinogenesis.
Although the presence of somatic PBRM1 mutations is already well established in biliary carcinoma, little is known about the timing of PBRM1 mutations during biliary carcinogenesis. Such knowledge would provide insights into the basic mechanism of tumour suppression by chromatin remodellers in biliary carcinogenesis and may also provide novel strategies for early detection of biliary neoplasia. PBRM1 mutations are inactivating and result in a loss of protein expression, and previous studies have demonstrated that loss of protein expression on immunohistochemistry correlates strongly with mutational status of PBRM1, as well as for other chromatin remodelling genes. [10] [11] [12] [13] [14] In order to determine the timing of PBRM1 mutations, we have assayed PBRM1 protein expression in a series of precursor lesions and invasive carcinomas, including both intrahepatic and gallbladder lesions, representing a broad sample of the spectrum of biliary neoplasia. In addition, as PBRM1 expression has been identified recently as a prognostic factor in several tumour types, [15] [16] [17] we have analysed the correlation of overall survival and PBRM1 status in our ICC cohort. The biliary dysplasia was classified according to consensus criteria, with three histological grades: biliary intra-epithelial neoplasm (BilIN) 1, BilIN-2 and BilIN-3.
Materials and methods

C A S E S E L E C T I O N
18-20 Similar three-tiered criteria were also employed for classification of mass-forming biliary dysplasia, with distinction of low-, intermediate-and high-grade dysplasia. 20 All cases with a consensus diagnosis of BilIN were analysed with immunohistochemistry for PBRM1, as described below. In addition, we included additional ICCs not associated with biliary dysplasia. These cancers were subclassified further in type 1 (also known as large duct variant) and type 2 (also known as small duct variant) ICCs, according to a recently proposed classification based on histological features. 21, 22 Cases of gallbladder dysplasia and carcinoma were obtained from gallbladder resection specimens from Johns Hopkins Hospital referred to an expert biliary pathologist (P.A.) for classification. These cases were then classified independently by two pathologists (C.L., L.D.W.), using the standardized BilIN classification system. 18 For all cases with multi-focal BilIN, we analysed only the BilIN with the highest grade of dysplasia.
I M M U N O H I S T O C H E M I S T R Y A N D S U R V I V A L A N A L Y S I S
Because PBRM1 mutations result in a loss of protein expression, we used an immunohistochemical approach to study PBRM1 mutational status. 2 As a further control, we included six ICCs with known PBRM1 mutational status (four wild-type and two mutated), which were analysed in our initial wholeexome sequencing study of cholangiocarcinoma. 2 This immunohistochemical method allowed us investigate the mutational status in dysplastic lesions that were too small to be analysed by sequencing.
Immunohistochemistry for PBRM1 was conducted using the Benchmark XT automated stainer (Ventana, Tucson, AZ, USA), as described previously. 11 Briefly, formalin-fixed, paraffin-embedded tissue sections were cut at 3-4 lm and air-dried overnight. The sections were deparaffinized, rehydrated and subjected to heat-induced epitope retrieval with Trisbased cell-conditioning buffer solution (Ventana). Sections were then incubated with an appropriate primary antibody (source: Bethyl Laboratories Inc., Montgomery, TX, USA; type: rabbit polyclonal; dilution 1:250; incubation: 32 min). For signal detection, the ultraView universal detection system (Ventana) was used. The slides were developed using 3-3 0 -diaminobenzidine chromogen and counterstained with haematoxylin. Appropriate positive and negative controls were utilized for each run of immunostains. Nuclear positivity indicated PBRM1 expression (PBRM1 wild-type); the lack of staining indicated PBRM1 loss (PBRM1 mutation). This entire immunohistochemical process for PBRM1 was validated using a cohort of 176 clear cell renal cell carcinomas with known mutation status. 1 The possible prognostic role of PBRM1 expression in our ICC cohort was analysed with a multivariate analysis adjusted for clinical and pathological features [age, gender, tumour grade, type of surgery and tumour-node-metastasis (TNM) stage] using a Cox's regression analysis, as well as with a Kaplan-Meier curve.
Results
C A S E S E L E C T I O N
Examination of ICCs led to identification of 15 associated BilINs (Table 1) . Among these, five were BilIN-1, six were BilIN-2 and four were BilIN-3. A similar number of ICCs without associated dysplastic lesions were also included to confirm the mutation prevalence of PBRM1 in ICC. Although these 14 cases were selected without knowledge of PBRM1 status, six were included in a previous whole-exome sequencing study. The analysed ICCs included five type 1 (large duct) carcinomas, 22 type 2 (small duct) carcinomas and two carcinomas with mixed features.
The evaluation of liver explants with hepatolithiasis, PBC and PSC identified two cases of hepatolithiasis with dysplasia (both BilIN-1), one case of PBC with dysplasia (BilIN-1) and six dysplastic cases among PSC (three BilIN-1, two BilIN-2 and one BilIN-3). Representative intrahepatic BilINs are shown in Figure 1A -C.
The gallbladder cases included three cases with invasive adenocarcinoma associated with BilIN (two BilIN-1 and one BilIN-3) (Table 1) . Furthermore, three cases with a microinvasive adenocarcinoma (<5 mm) associated with BilIN were identified: the BilIN were all BilIN-3.
3 There were also 10 BilIN lesions of the gallbladder not associated with an invasive component: three were BilIN-1, two were BilIN-2 and five were BilIN-3. Representative BilINs from the LGD, Low-grade dysplasia; IGD, Intermediate-grade dysplasia; HGD, High-grade dysplasia; BiiIN, Biliary intra-epithelial neoplasia.
gallbladder are shown in Figure 1D -F. Our cohort also included four intracystic papillary neoplasms of the gallbladder, two with low-grade dysplasia and two with high-grade dysplasia.
Expression of PBRM1 in neoplastic cells by immunohistochemistry was evaluated with a binary scoring system: lost (immunohistochemistry-negative) or retained (immunohistochemistry-positive) (Figure 2 ). Importantly, in our ICC cases with known PBRM1 mutation status, there was a perfect correlation between immunohistochemical staining and PBRM1 mutation status: the two cases with PBRM1 mutations showed loss of PBRM1 protein expression, and the four wild-type cases retained PBRM1 expression.
The immunohistochemistry results are summarized in Table 2 . Among ICC, seven of 29 cases (24%) showed loss of PBRM1 on immunohistochemistry ( Figure 2) ; of these, five were associated with BilIN and two were not. We identified PBRM1 loss in one of five type 1 cancers (20%), five of 22 type 2 cancers (23%) and one of two mixed-type cancers (50%). At the same time, among the 15 biliary dysplasia (BilIN-1, -2 and -3) associated with ICC, no cases presented PBRM1 loss, including the five with an associated PBRM1-negative cholangiocarcinoma (Figure 2 ). The prevalence of PBRM1 loss was significantly higher in cancer compared to BilIN (P < 0.01, Fisher's exact test).
The results of PBRM1 immunohistochemistry in BilINs unassociated with cholangiocarcinoma were similar to those of BilINs associated with cholangiocarcinoma described above. Among the nine cases of BilIN in hepatolithiasis, PBC and PSC, no cases showed PBRM1 loss on immunohistochemistry.
Among the gallbladder cases, only one case of invasive carcinoma showed PBRM1 loss; the rest of the cases showed a retained expression of PBRM1. Notably, one intracystic papillary neoplasm with high-grade dysplasia demonstrated a small portion of the lesion (approximately 20%) with PBRM1 loss, but in the rest of the lesion PBRM1 was expressed clearly (Figure 3 ). Clinical and pathological data for survival analysis were available for 24 ICC patients. With a multivariate analysis, the loss of PBRM1 was not associated with any increased risk of mortality [hazard ratio (HR) = 1.19; 95% confidence interval (CI) = 0.06-22.31; P = 0.59], as also shown in the Kaplan-Meier curve (Figure 4 ).
Discussion
Our study demonstrates that loss of PBRM1 expression is limited to cases of invasive cancer; neither biliary dysplastic lesions (in the liver or gallbladder) nor microinvasive cancers (in the gallbladder) showed loss of PBRM1 on immunohistochemical analysis. Overall, our results suggest that PBRM1 mutation is a late event during biliary carcinogenesis in the liver and gallbladder.
ICC can be subclassified into two histological subtypes: large duct type (type 1) and small duct type (type 2). [20] [21] [22] Recently, Misumi et al. reported that PBRM1 mutations occurred at similar prevalence in both subtypes (42% in type 1 and 53% in type 2), suggesting molecular similarities between the subtypes. 10 Our results are in line with these previous findings, with a similar prevalence of PBRM1 loss between the two subtypes. Although the prevalence of PBRM1 loss was lower in our study (20-30% in each group), the lower number of cases in our series might contribute to this discrepancy. In addition, the results of our survival analysis confirm the finding of Misumi et al. that PBRM1 expression does not have a prognostic role in ICC. Notably, in contrast to ICC, PBRM1 expression has been shown to impact survival significantly in other solid malignancies with PBRM1 mutations. [15] [16] [17] It has been hypothesized that biliary carcinoma may develop through two key premalignant precursor lesions: BilIN (flat dysplasia) and intraductal/ A C B Figure 2 . Immunohistochemistry for Polybromo-1 (PBRM1) in dysplastic and malignant biliary lesions. A, Intrahepatic cholangiocarcinoma with retained nuclear PBRM1 expression; B, intrahepatic cholangiocarcinoma with loss of nuclear PBRM1 -this expression pattern is correlated with mutations in the PBRM1 gene; C, biliary intra-epithelial neoplasia (BilINs) with retained nuclear PBRM1 expression. No BilIN lesions showed loss of nuclear PBRM1 expression. intracystic papillary neoplasm (mass-forming lesions). 18, 19, [23] [24] [25] However, somatic mutations in key driver genes have been identified in BilINs only in patients with specific risk factors (i.e. hepatolithiasis). 16 We hypothesize that this is because the alterations assayed to date are late events in biliary carcinogenesis, but an alternative explanation for the lack of driver alterations is that BilINs are not, in fact, precursors to cholangiocarcinoma. BilINs have been proposed as a precursor for only type 1 ICC, 21, 26 but PBRM1 mutations occur at similar frequency in both subtypes of ICC. 10 The lack of PBRM1 loss in BilINs suggests that alterations in this gene are a late event, at least in the tumorigenesis of type 1 ICC. Of note, there is considerable controversy over the identity of the precursor lesion of type 2 ICC, so it is not possible to address the timing of PBRM1 loss in this subtype. Nevertheless, BilINs found in livers with type 2 ICC are relevant -each BilIN is not an obligate precursor of the concomitant carcinoma but instead may be an isolated dysplastic lesion.
Sasaki et al. recently reported a study on the expression of another chromatin remodelling gene, ARID1A, in cholangiocarcinoma and its precursors. 27 Loss of ARID1A expression was detected by immunohistochemistry biliary carcinomas but not in any of the dysplastic lesions analysed, which included both BilINs and biliary mass-forming dysplastic lesions. 27 In keeping with our results, this study highlights further that mutations in chromatin remodelling genes are late events in biliary carcinogenesis, occurring predominantly in invasive carcinoma. In contrast, in other organs mutations in chromatin remodellers have been suggested as an early event during carcinogenesis; this has been reported previously for oesophageal cancer, as well as ovarian and endometrial cancers. 28, 29 This suggests that somatic alterations in chromatin remodellers may play different roles in different organs, as the timing during tumorigenesis is widely disparate.
Notably, in our series, a case of intracystic papillary neoplasm with high-grade dysplasia presented a focal loss of PBRM1 expression ( Figure 3) ; this was the only dysplastic lesion with an abnormal PBRM1 expression. This finding raises the possibility that PBRM1 loss may be involved in earlier stages in the biliary carcinogenesis via mass-forming dysplastic lesions compared to BilIN, and highlights the concept of intra-tumour heterogeneity in preneoplastic lesions. Future experiments could assess this heterogeneity with targeted next-generation sequencing to confirm the results of the immunohistochemistry. However, the true prevalence of these early mutations in intracystic papillary neoplasms remains to be determined, as we had only four cases in our cohort.
Our study has some limitations. Due to the rarity of biliary intra-epithelial neoplasia, the number of cases analysed in this study is limited. This issue is particularly relevant for mass-forming dysplastic lesions, as only four cases of these rare lesions were included in our study. Our study also excluded intraductal papillary neoplasms of the bile duct and, as such, follow-up studies will be required to determine the role (if any) of PBRM1 loss in these lesions. In addition, our ICC cohort included a relatively small number of type 1 (large duct) ICC, suggesting that the majority of the BilINs analysed in these patients were concomitant with, rather than precursors to, the co-occurring ICC. Although these cases are still informative, it should be noted that we only analysed one PBRM1-mutant type 1 ICC that had the potential to demonstrate PBRM1 loss in a matched ICC/BilIN pair. The grading of biliary dysplasia is a subjective process. It is possible that some cases, particularly those diagnosed as low-grade dysplasia (BilIN-1), in fact represent reactive atypia. Such inaccurate categorization could contribute to the low prevalence of PBRM1 alterations demonstrated in our study. However, to minimize the risk of misclassification, we evaluated each case in a rigorous stepwise review involving three pathologists, including experts in biliary neoplasia. Moreover, although it is possible that cases diagnosed as BilIN-1 might truly represent reactive atypia, this is far less likely for higher grades of dysplasia. In our study, all grades of BilIN lacked PBRM1 alterations, suggesting that our conclusions are robust despite the inherent subjectivity in BilIN diagnosis.
In conclusion, based on immunohistochemical analysis of PBRM1 expression in BilIN lesions, we found that PBRM1 mutations are a late event during cholangiocarcinogenesis.
These results have implications for the functional role of chromatin remodelling genes in biliary tumorigenesis. 
